Creating a free account will enable you to subscribe to our daily and weekly email newsletters, as well as customize your reading experience to show only the categories most relevant to you.
Signing up only take a few minutes, so why not give it a try and see what you've been missing out on.
New research suggests that a single dose of the human papillomavirus vaccine could be enough to protect women against cervical cancer. This is according to a study published in the journal Cancer Prevention Research.
According to the Centers for Disease Control and Prevention (CDC), around 79 million Americans are infected with the human papillomavirus (HPV), and approximately 14 million people will become infected each year.
Every year, around 26,000 new cancers occur in the US as a result of HPV, says the CDC. Of these, 18,000 are among women, and 11,500 are cases of cervical cancer.
Current guidelines recommended that these vaccines should be administered for girls in a series of three shots at age 11 or 12, or for girls aged 13 to 26 who have not yet been vaccinated.
However, a CDC report release this year detailing the vaccination coverage among adolescent girls between 2006 and 2013, revealed that only 53.8% of girls aged between 13 and 17 had the HPV vaccine, and of these, only 33.4% had all three doses.
From this, researchers from the US, Costa Rica, the Netherlands and France set out to determine whether one or two does of the Cervarix HPV vaccine may have similarly protective effects against HPV.
Using data from a phase III trial funded by the National Cancer Institute (NCI) to test the effectiveness of Cervarix in women from Costa Rica, the researchers found that around 20% of these women had not received the full three doses of the HPV vaccine.
The researchers then measured the antibody levels in blood samples from the women, in order to detect presence of an immune response to the vaccine. The blood samples were taken from 78 women who received one dose of the vaccine, 192 women who received two doses, and 120 women who received three doses.
The results revealed that 100% of these women in all three groups showed the presence of antibodies against HPV 16 and 18 - the two HPV types that can cause cervical cancer - for up to 4 years.
Although antibody levels were lower from the women who received one dose, compared with those who received three doses, the levels still appeared stable.
The researchers note that these findings suggest the preventive effects of even one dose of the vaccine are long-lasting.
Furthermore, it was found that antibody levels in women who received one or two doses of the HPV vaccine were 24 times higher, compared with women who did not receive the vaccination at all but who had HPV infection previously.
Mahboobeh Safaeian, of the Division of Cancer Epidemiology and Genetics at the NCI, says their findings "challenge previous dogma" that these vaccines need multiple doses to achieve long-term effectiveness.
"Our findings suggest promise for simplified vaccine administration schedules that might be cheaper, simpler, and more likely to be implemented around the world.
Vaccination with two doses, or even one dose, could simplify the logistics and reduce the cost of vaccination, which could be especially important in the developing world, where more than 85% of cervical cancers occur, and where cervical cancer is one of the most common causes of cancer-related deaths."
Safaeian says that in some parts of the world, such as Chile and British Columbia, two doses of the HPV vaccine is already within the standard recommended vaccination program.
But she notes that although these study findings show that one does of the vaccine also provides long-term effects, further research is needed before any policy guidelines can be changed.
"For instance," she adds, "it is important to note that persistence of antibody responses after a single dose has not been evaluated for Gardasil, the quadrivalent HPV vaccine that is more widely used in the United States and many other countries."
Earlier this year, Medical News Today reported on research suggesting that parents' worries regarding the HPV vaccine prevent girls from receiving it.
Written by Honor Whiteman
Copyright: Medical News Today
Not to be reproduced without the permission of Medical News Today.
Durable Antibody Responses Following One Dose of the Bivalent Human Papillomavirus L1 Virus-Like Particle Vaccine in the Costa Rica Vaccine Trial, Mahboobeh Safaeian, Carolina Porras, Yuanji Pan, Aimee Kreimer, John T. Schiller, Paula Gonzalez, Douglas R. Lowy, Sholom Wacholder, Mark Schiffman, Ana C. Rodriguez, Rolando Herrero, Troy Kemp, Gloriana Shelton, Wim Quint, Leen-Jan van Doorn, Allan Hildesheim, Ligia A. Pinto, published in Cancer Prevention Research, 4 November 2013.
Visit our Cervical Cancer / HPV Vaccine category page for the latest news on this subject.
Please use one of the following formats to cite this article in your essay, paper or report:
Whiteman, Honor. "One HPV vaccine dose 'enough' for cervical cancer prevention." Medical News Today. MediLexicon, Intl., 4 Nov. 2013. Web.
12 Dec. 2013. <http://www.medicalnewstoday.com/articles/268291>
Whiteman, H. (2013, November 4). "One HPV vaccine dose 'enough' for cervical cancer prevention." Medical News Today. Retrieved from
Please note: If no author information is provided, the source is cited instead.
If you write about specific medications, operations, or procedures please do not name healthcare professionals by name.
For any corrections of factual information, or to contact the our editorial team, please use our feedback form. Please send any medical news or health news press releases to:
Note: Any medical information published on this website is not intended as a substitute for informed medical advice and you should not take any action before consulting with a health care professional. For more information, please read our terms and conditions.
This page was printed from: http://www.medicalnewstoday.com/articles/268291.php
Visit www.medicalnewstoday.com for medical news and health news headlines posted throughout the day, every day.
© 2004-2013 All rights reserved. MNT (logo) is the registered trade mark of MediLexicon International Limited.